阿布希替尼治疗青斑样血管病一例并文献复习
A Case of Livedoid Vasculopathy Treated with Abroctinib and Literature Review
DOI: 10.12677/acm.2024.1492544, PDF,   
作者: 陈 洋：青岛大学附属医院皮肤科，山东 青岛；中国人民解放军海军第九七一医院皮肤病科，山东 青岛；张可洲, 朱 琪, 逄 凤：中国人民解放军海军第九七一医院皮肤病科，山东 青岛；王 君*：青岛大学附属医院皮肤科，山东 青岛
关键词: 阿布希替尼；青斑样血管病；JAK抑制剂；Abroctinib； Livedoid Vasculopathy； JAK Inhibitor
摘要: 青斑样血管病的传统治疗主要有系统性使用抗凝药物、抗血小板药物、免疫抑制剂、糖皮质激素及物理治疗等，常因不良反应及疗效不佳而使用受限。近年来，小分子靶向药物(JAK抑制剂)已经被越来越多用于治疗炎症性皮肤病，取得满意的临床效果及良好的安全性。本文报道JAK1抑制剂阿布希替尼治疗青斑样血管病1例，并回顾相关文献。
Abstract: The traditional treatment of livedoid vasculopathy mainly includes systemic use of anticoagulants, antiplatelet drugs, immunosuppressive agents, glucocorticoids and physical therapy, which is often limited due to adverse reactions and poor efficacy. In recent years, small molecule targeted drugs (JAK inhibitors) have been more and more used in the treatment of inflammatory skin diseases, achieving satisfactory clinical results and good safety. This paper reports the treatment of JAK 1 inhibitor Abxitinib in a case of blue spot-like vascular disease, and reviews the relevant literature.
文章引用：陈洋, 张可洲, 朱琪, 逄凤, 王君. 阿布希替尼治疗青斑样血管病一例并文献复习[J]. 临床医学进展, 2024, 14(9): 903-907. https://doi.org/10.12677/acm.2024.1492544

参考文献

[1] 闫雨荷, 崔炳南, 吴小红, 等. 青斑样血管病的诊疗进展[J]. 中国麻风皮肤病杂志, 2017, 33(4): 254-256.
[2] Jia, E., Yan, G., Xiao, M., Geng, H., Wei, J. and Zhang, J. (2020) Refractory Ulcerations Associated with Livedoid Vasculopathy Successfully Treated with Tofacitinib. Dermatologic Therapy, 33, e14470. [Google Scholar] [CrossRef] [PubMed]
[3] Zhang, H., Chen, J., Wu, N., Chen, H. and Liu, Y. (2022) Refractory Livedoid Vasculopathy in a Child Successfully Treated with Baricitinib. Dermatologic Therapy, 35, e15659. [Google Scholar] [CrossRef] [PubMed]
[4] Feldaker, M., Hines Jr., E.A. and Kierland, R.R. (1955) Livedo Reticularis with Summer Ulcerations. Archives of Dermatology, 72, 31-42. [Google Scholar] [CrossRef] [PubMed]
[5] Criado, P.R., Rivitti, E.A., Sotto, M.N., Valente, N.Y.S., Aoki, V., de Carvalho, J.F., et al. (2011) Vasculopatia Livedoide: Uma doença cutânea intrigante. Anais Brasileiros de Dermatologia, 86, 961-977. [Google Scholar] [CrossRef] [PubMed]
[6] 高祎濛, 晋红中. 青斑样血管病发病机制[J]. 中华临床免疫和变态反应杂志, 2020, 14(5): 479-484.
[7] Micieli, R. and Alavi, A. (2018) Treatment for Livedoid Vasculopathy. JAMA Dermatology, 154, 193-202. [Google Scholar] [CrossRef] [PubMed]
[8] Dong, L., Li, Q., Yu, Y., Liang, J. and Zhang, X. (2022) Efficacy of Adalimumab in the Treatment of Refractory Livedoid Vasculopathy: Case Report and Literature Review. Dermatologic Therapy, 35, e15666. [Google Scholar] [CrossRef] [PubMed]
[9] Gao, Y. and Jin, H. (2020) Efficacy of an Anti-TNF-Alpha Agent in Refractory Livedoid Vasculopathy: A Retrospective Analysis. Journal of Dermatological Treatment, 33, 178-183. [Google Scholar] [CrossRef] [PubMed]
[10] Huang, X., Zheng, H., Wang, M., He, W., Feng, M., Zeng, K., et al. (2022) Adalimumab in Treating Refractory Livedoid Vasculopathy. Vaccines, 10, Article 549. [Google Scholar] [CrossRef] [PubMed]
[11] Song, X. and Tu, P. (2022) Treatment of Livedoid Vasculopathy with Baricitinib. JAMA Dermatology, 158, 587-589. [Google Scholar] [CrossRef] [PubMed]
[12] Peñuelas Leal, R., Grau Echevarría, A., Martínez Domenech, Á., Labrandero Hoyos, C., Zaragoza Ninet, V., Sanchez Carazo, J.L., et al. (2023) Refractory Livedoid Vasculopathy Successfully Treated with Baricitinib. International Journal of Dermatology, 62, e608-e610. [Google Scholar] [CrossRef] [PubMed]
[13] Xiao, Y., Wang, Y., Gu, Y., Xia, D. and Li, W. (2022) Refractory Livedoid Vasculopathy Successfully Treated with Baricitinib. International Journal of Dermatology, 62, 1204-1205. [Google Scholar] [CrossRef] [PubMed]
[14] Han, Y. and Tu, P. (2022) Baricitinib Is Potentially Effective in the Treatment of Refractory Livedoid Vasculopathy. Frontiers in Immunology, 13, Article 1008392. [Google Scholar] [CrossRef] [PubMed]
[15] Cartron, A.M., Nguyen, T.H., Roh, Y.S., Kwatra, M.M. and Kwatra, S.G. (2021) Janus Kinase Inhibitors for Atopic Dermatitis: A Promising Treatment Modality. Clinical and Experimental Dermatology, 46, 820-824. [Google Scholar] [CrossRef] [PubMed]
[16] Seavey, M.M. and Dobrzanski, P. (2012) The Many Faces of Janus Kinase. Biochemical Pharmacology, 83, 1136-1145. [Google Scholar] [CrossRef] [PubMed]
[17] He, H. and Guttman-Yassky, E. (2018) JAK Inhibitors for Atopic Dermatitis: An Update. American Journal of Clinical Dermatology, 20, 181-192. [Google Scholar] [CrossRef] [PubMed]
[18] Samuel, C., Cornman, H., Kambala, A. and Kwatra, S.G. (2023) A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring. Dermatology and Therapy, 13, 729-749. [Google Scholar] [CrossRef] [PubMed]
[19] Chen, P., Liang, J., Li, C., Li, Q., Liu, W., Zhu, J., et al. (2024) Abrocitinib as a Novel Treatment for Multiple Skin Disorders: 3 Case Reports and a Scoping Review. Clinical, Cosmetic and Investigational Dermatology, 17, 35-40. [Google Scholar] [CrossRef] [PubMed]
[20] Bennett, M., Moussa, A. and Sinclair, R. (2022) Successful Treatment of Chronic Severe Alopecia Areata with Abrocitinib. Australasian Journal of Dermatology, 63, 274-276. [Google Scholar] [CrossRef] [PubMed]
[21] Solimani, F., Mesas‐Fernández, A., Dilling, A., Nast, A., Hilke, F.J., Ghoreschi, F.C., et al. (2023) The Janus Kinase 1 Inhibitor Abrocitinib for the Treatment of Oral Lichen Planus. Journal of the European Academy of Dermatology and Venereology, 37, e996-e998. [Google Scholar] [CrossRef] [PubMed]
[22] Arnet, L. and Erfurt‐Berge, C. (2023) Effect of Abrocitinib in a Patient with Extensive Necrobiosis Lipoidica. Journal of the European Academy of Dermatology and Venereology, 37, e1208-e1210. [Google Scholar] [CrossRef] [PubMed]
[23] 叶慧, 朱君慧, 陈伟锋, 等. 阿布昔替尼治疗青斑样血管病一例[J]. 中国麻风皮肤病杂志, 2024, 40(3): 196-198.

为你推荐